Myeloma Research and Education

5.4myelomaMinBannerTemplateNew1.png

| INNOVATION | Video

490x245ConfSeriesReplay.png

2018 IMWG Conference Series,
“The Role of Mass Spectrometry”

In this video, IMF Chairman Brian G.M. Durie moderates a lively discussion about mass spectrometry with Dr. Joseph Mikhael (IMF Chief Medical Officer) and Dr. Sagar Lonial (Emory University, Atlanta). This video is the first in a six-part series that focuses on making sense of multiple myeloma treatment based upon the newly obtained input from three leading research conferences: the American Society of Clinical Oncology (ASCO) 2018 annual meeting, the International Myeloma Working Group (IMWG) 2018 Summit, and the European Hematology Association (EHA) annual meeting, which all took place during the first two weeks of June 2018.

LearnMoreButton.png

| EDUCATION | Teleconference

490x245LivingWellv2.png

Listen to a Replay of This ‘Living Well with Myeloma’ Teleconference

In case you missed it, the IMF presented “The Importance of Bone Health and Treatment Updates: What Patients and Caregivers Need to Know,” as part of the Living Well with Myeloma teleconference series. This 60-minute presentation with Noopur S. Raje, MD (Massachusetts General Hospital Cancer Center, Boston) and Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN (Cleveland Clinic Taussig Cancer Institute, Cleveland) is now available as a replay.

listenNowButton.png

| INSPIRATION | Fundraiser

200x200laugh4life.png

| INNOVATION | Clinical Trials

ClinicalTrial200x200.png

Laughs 4 Life Comedy Benefit

ELOQUENT-3 Trial Results

On Wednesday, August 1, 2018, comedians Tig Notaro, Nate Bargatze, and others will perform at 7:30 p.m. EST at the Saenger Theater (201 Forest St.) in Hattiesburg, Mississippi, as part of Laughs for Life. Proceeds from this event will benefit the International Myeloma Foundation’s research initiatives.

The international phase II study, the ELOQUENT-3 trial, reached its primary endpoint. This trial compares the combination Empliciti (elotuzumab)+ pomalidomide + low-dose dexamethasone (EPd) with the combination of pomalidomide + dexamethasone (Pd) in patients with relapsed/refractory multiple myeloma (RRMM). The trials shows “statistically significant and clinically meaningful improvement in progression-free survival (PFS)” for patients treated with EPd compared with Pd alone.

LearnMoreButton.png

LearnMoreButton.png

| EDUCATION | Event

490x245RCWEdina.png

Register NOW for a Regional Community Workshop in Edina, Minnesota

The IMF will conduct a Regional Community Workshop in Edina, MN, on Saturday, July 21, 2018. Registration is FREE, but seating is limited. This is a wonderful opportunity to learn from and meet one-on-one with myeloma experts Craig Cole, MD (University of Michigan, Ann Arbor, MI); Martha Lacy, MD, Professor of Medicine (Mayo Clinic, Rochester, MN); and Teresa Miceli, RN, BSN, OCN (Mayo Clinic-College of Medicine, Rochester, MN).

registerNowButton.png

| ADVOCACY | Health Insurance

490x245advocacy.png

Department of Labor Issues Final Rule for Association Health Plans

The Department of Labor issued a final rule for Association Health Plans on June 19, 2018. This rule is intended to make it easier for people to come together to purchase health coverage outside of the Affordable Care Act (Obamacare) insurance markets. These plans do not have to follow the same rules as policies sold under Obamacare, which is the cause of alarm for many, particularly patient advocates.

The proponents of this rule feel that by providing additional flexibility, the rule will decrease premiums and provide consumers with more selection. The opponents of this rule argue these plans do not include the same patient protections as Obamacare plans. Furthermore, the opponents of the rule fear it could harm the Obamacare markets by enticing healthier, younger people off the exchanges in favor of these cheaper alternatives.

While the rule does contain language prohibiting insurers from denying coverage or charging more money to a person with a preexisting condition, it still allows plans to exclude essential health benefits (EHBs). It is important to note that without EHBs, your plan may not cover the medications or services you need.

LearnMoreButton.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series

DurieVideoBox6.21.18.png

CLINICAL TRIALS

EVENTS

BOSTON Trial Fact Sheet

New isatuximab Clinical Trial: the IMROZ Study

New isatuximab Clinical Trial: the IKEMA Study

New ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

Ongoing
Putting a Lid on Myeloma
Central Florida

July 21, 2018
IMF Regional Community Workshop
Edina, MN

August 1, 2018
Laughs for Life
Hattiesburg, MS

August 24-25, 2018
IMF Patient & Family Seminar
Los Angeles, CA

September 22, 2018
6th Annual Miracles for Myeloma 5K Race/Walk
Oak Ridge Park Clark, NJ

September 22, 2018
A Mission for Matt
Mineola, NY

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year